Last reviewed · How we verify

Chidamide in combination with Ivonescimab

Guangdong Association of Clinical Trials · Phase 2 active Small molecule

Chidamide in combination with Ivonescimab is a Small molecule drug developed by Guangdong Association of Clinical Trials. It is currently in Phase 2 development. Also known as: Tucidinostat, CS055, AK112.

At a glance

Generic nameChidamide in combination with Ivonescimab
Also known asTucidinostat, CS055, AK112
SponsorGuangdong Association of Clinical Trials
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Chidamide in combination with Ivonescimab

What is Chidamide in combination with Ivonescimab?

Chidamide in combination with Ivonescimab is a Small molecule drug developed by Guangdong Association of Clinical Trials.

Who makes Chidamide in combination with Ivonescimab?

Chidamide in combination with Ivonescimab is developed by Guangdong Association of Clinical Trials (see full Guangdong Association of Clinical Trials pipeline at /company/guangdong-association-of-clinical-trials).

Is Chidamide in combination with Ivonescimab also known as anything else?

Chidamide in combination with Ivonescimab is also known as Tucidinostat, CS055, AK112.

What development phase is Chidamide in combination with Ivonescimab in?

Chidamide in combination with Ivonescimab is in Phase 2.

Related